SEP 02, 2019 12:47 PM PDT

Drug Reduces Heart Attacks in Diabetic Patients

WRITTEN BY: Nouran Amin

Recent results from a clinical trial that evaluated the addition of a drug called ‘ticagrelor’ to aspirin were shown to improve clinical outcomes for patients with stable coronary artery disease and diabetes mellitus. These patients in the study had no history of heart attack or stroke.

Findings from the clinical trial known as ‘The Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study (THEMIS), explained how the usage of ticagrelor with aspirin formed a dual-antiplatelet therapy that has reduced the risk of cardiovascular death, heart attack, and stroke. However, the study did show that patients on the dual therapy also experienced a greater risk of a major bleed and intracranial hemorrhage, particularly through an increased number of non-procedural subdural bleeds, in comparison to those who were on the placebo.

"With prolonged dual-antiplatelet therapy, we need to be thoughtful in considering which patients are most suited to taking the regimen -- that is, those at high ischemic risk and low bleeding risk," said THEMIS co-chair Deepak L. Bhatt, MD, MPH, executive director of Interventional Cardiovascular Programs at the Brigham and professor of medicine at Harvard Medical School. "Our findings show that the greatest benefit occurred in those patients with diabetes and stable coronary artery disease with a history of prior stenting for whom ticagrelor, when added to aspirin, reduced important cardiovascular events, such as heart attacks, strokes and amputations."

THEMIS is the largest clinical trial study involving diabetic patients to date with more than 19,000 participants who have stable coronary artery disease and diabetes that were randomly selected to receive either ticagrelor plus aspirin (the dual antiplatelet therapy) or a placebo plus aspirin. These patients were studied over the course of three years

"The THEMIS population is a critically important one in which to understand the potential benefits of taking ticagrelor in addition to aspirin. As the number of people with diabetes continues to rise globally, we need to evaluate ways of improving long-term outcomes and preventing cardiovascular and ischemic events,” says THEMIS co-chair Philippe Gabriel Steg, MD, Chief of Cardiology at Hôpital Bichat, Greater Paris University Hospitals.

Learn more about the heart disease-diabetes connection:

 

 

"Our results indicate that among those with diabetes and stable coronary artery disease, we should focus on ticagrelor for patients with a history of prior stenting. This is an easily identifiable, logical sub-group," said Bhatt. "Studies currently support using long-term dual antiplatelet therapy for patients with the acute coronary syndrome who are at high ischemic risk but low bleeding risk. Our work suggests that a much broader population of patients with stable coronary artery disease and diabetes stand to benefit substantially."

Source: Science Daily

 

About the Author
BS/MS
Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
APR 20, 2022
Drug Discovery & Development
Vitamin E Stimulates Dendritic Cells, Boosts Immunotherapy Effectiveness
APR 20, 2022
Vitamin E Stimulates Dendritic Cells, Boosts Immunotherapy Effectiveness
Dendritic cells play an important role in the immune system. Specifically, they help gather up antigen-presenting cells ...
MAY 11, 2022
Drug Discovery & Development
Gene Therapy Shows Promise for Neuropathic Pain
MAY 11, 2022
Gene Therapy Shows Promise for Neuropathic Pain
A gene therapy has been able to inhibit neuropathic pain with no detectable side effects in mice with spinal cord and pe ...
MAY 25, 2022
Neuroscience
Exploring Drug Targets in Neurodegenerative Diseases
MAY 25, 2022
Exploring Drug Targets in Neurodegenerative Diseases
Introduction Life expectancy has increased globally over the last several decades. However, longer life expectancy comes ...
MAY 22, 2022
Drug Discovery & Development
Gout Medication Helps Hospitalized People with Heart Failure
MAY 22, 2022
Gout Medication Helps Hospitalized People with Heart Failure
A research team at the University of Virginia Hospital System found that a regularly-used medication for gout, called co ...
JUN 14, 2022
Cancer
Maintaining Sample Temperature: Q&A From a Corning Scientist
JUN 14, 2022
Maintaining Sample Temperature: Q&A From a Corning Scientist
Generally speaking, bad things can happen when a cell sample temperature gets too hot or too cold. Temperature instabili ...
JUN 07, 2022
Cell & Molecular Biology
Advances in Laboratory Automation Research at the 2022 Labroots Virtual Event
JUN 07, 2022
Advances in Laboratory Automation Research at the 2022 Labroots Virtual Event
Labroots hosted its 6th Annual Laboratory Automation Virtual Event on May 18, 2022. The speaker roster for this free con ...
Loading Comments...